Biopsy of breast cancer metastases: patient characteristics and survival
暂无分享,去创建一个
G. Bar-Sela | H. Muss | K. Drumea | S. Shachar | G. Fried | N. Shafran | T. Mashiach | G. Bar-Sela | S. S. Shachar
[1] Maria Adler,et al. Multivariable Analysis A Practical Guide For Clinicians , 2016 .
[2] A. Jemal,et al. Cancer statistics, 2016 , 2016, CA: a cancer journal for clinicians.
[3] R. Bast,et al. Use of Biomarkers to Guide Decisions on Systemic Therapy for Women With Metastatic Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] M. Cristofanilli,et al. Molecular characterization and targeted therapeutic approaches in breast cancer , 2015, Breast Cancer Research.
[5] Sung-Bae Kim,et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. , 2015, The New England journal of medicine.
[6] M. Fernö,et al. Molecular subtype and tumor characteristics of breast cancer metastases as assessed by gene expression significantly influence patient post-relapse survival , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[7] M. Somerfield,et al. Use of Biomarkers to Guide Decisions on Systemic Therapy for Women With Metastatic Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. , 2015, Journal of oncology practice / American Society of Clinical Oncology.
[8] J. Bergh,et al. Breast cancer during follow-up and progression - A population based cohort on new cancers and changed biology. , 2014, European journal of cancer.
[9] M. Özgüroğlu,et al. Receptor Expression Discrepancy between Primary and Metastatic Breast Cancer Lesions , 2014, Oncology Research and Treatment.
[10] M. Piccart,et al. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)† , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[11] Yan-Fang Xie,et al. Discordances in ER, PR and HER2 receptors between primary and recurrent/metastatic lesions and their impact on survival in breast cancer patients , 2014, Medical Oncology.
[12] A. Goldhirsch,et al. A meta-analysis of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 discordance between primary breast cancer and metastases. , 2014, European journal of cancer.
[13] Cheng Xu,et al. The importance of biopsy in clinically diagnosed metastatic lesions in patients with breast cancer , 2014, World Journal of Surgical Oncology.
[14] Luca Fumagalli,et al. Biopsy confirmation of metastatic sites in breast cancer patients: clinical impact and future perspectives , 2014, Breast Cancer Research.
[15] Hodgkin Lymphoma. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines , 2014 .
[16] X. Pivot,et al. Discordances in estrogen receptor status, progesterone receptor status, and HER2 status between primary breast cancer and metastasis. , 2013, The oncologist.
[17] F. André,et al. Discrepancies between primary tumor and metastasis: a literature review on clinically established biomarkers. , 2012, Critical reviews in oncology/hematology.
[18] A. Thompson,et al. Tissue confirmation of disease recurrence in breast cancer patients: pooled analysis of multi-centre, multi-disciplinary prospective studies. , 2012, Cancer treatment reviews.
[19] Mark Clemons,et al. Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] A. Thompson,et al. Prospective comparison of switches in biomarker status between primary and recurrent breast cancer: the Breast Recurrence In Tissues Study (BRITS) , 2010, Breast Cancer Research.
[21] L. Pusztai,et al. Estrogen and HER-2 receptor discordance between primary breast cancer and metastasis. , 2010, The oncologist.
[22] Pieter Wesseling,et al. Receptor conversion in distant breast cancer metastases , 2010, Breast Cancer Research.
[23] M. Kleinpeter. Multivariable Analysis: A Practical Guide for Clinicians, 2nd edition edited by Katz, M. H. Study Design and Statistical Analysis: A Practical Guide for Clinicians edited by Katz, M. H. , 2007 .
[24] S. Devesa,et al. Probabilities of death from breast cancer and other causes among female breast cancer patients. , 2004, Journal of the National Cancer Institute.
[25] T. Fleming,et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.
[26] R. Elledge,et al. Tumor characteristics and clinical outcome of elderly women with breast cancer. , 2000, Journal of the National Cancer Institute.
[27] N. Dubrawsky. Cancer statistics , 1989, CA: a cancer journal for clinicians.
[28] M. Brennan,et al. The variability of estrogen receptors in metastatic breast cancer. , 1979, American journal of surgery.